AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24016068 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between negative emotion and carrying rs1042718 or rs1042719 minor allele
Number of subjects: 877
Study 24016068 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise and social-leisure activities
Number of subjects: 877
Study 24016068 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotion
Number of subjects: 877
Study 21051752 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 173
Study 21051752 — intervention group
Group type: COMPARATOR
Intervention: CNI
Number of subjects: 173
Study 19032505 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Health Programme (twice weekly during working hours, including physical exercise, stress management training, health information, and workplace examination)
Number of subjects: 40
Study 19032505 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Health Programme
Number of subjects: 40
Study 19032505 — intervention group
Group type: COMPARATOR
Intervention: Control group (offered the same intervention after the project)
Number of subjects: 40
Study 18018351 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0
Study 18018351 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 15013730 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment (randomly intermixed presumed easy and hard teaching tasks)
Number of subjects: 4
Study 15013730 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment
Number of subjects: 4
Study 11680444 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol therapy (1 mg of estradiol-17beta per day)
Number of subjects: 664
Study 11680444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study 9129469 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months with ad libitum breast-feeding from 4 to 6 months (SF)
Number of subjects: 141
Study 9129469 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued full breast-feeding until 6 months (FBF)
Number of subjects: 141
Study 9129469 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of complementary foods at 4 months with maintenance of baseline breast-feeding frequency from 4 to 6 months (SF-M)
Number of subjects: 141
Study 7930337 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 134
Study 7930337 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Carrol Depression Rating Scale (BCDRS)
Number of subjects: 134
Study 7930337 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Geriatric Depression Scale (SGDS)
Number of subjects: 134
Study 7930337 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Scale (CES-D)
Number of subjects: 134
Study 3349550 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml coffee with oral ranitidine 150 mg (Group 4)
Number of subjects: 300
Study 3349550 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml orange juice with oral ranitidine 150 mg (Group 5)
Number of subjects: 300
Study 3349550 — intervention group
Group type: EXPERIMENTAL
Intervention: oral ranitidine alone (Group 6)
Number of subjects: 300
Study 30304656 — intervention group
Group type: EXPERIMENTAL
Intervention: Early strategy for renal-replacement therapy (within 12 hours after documentation of failure-stage acute kidney injury)
Number of subjects: 488
Study 30304656 — intervention group
Group type: COMPARATOR
Intervention: Delayed strategy for renal-replacement therapy (after a delay of 48 hours if renal recovery had not occurred)
Number of subjects: 488
Study 30304656 — intervention group
Group type: COMPARATOR
Intervention: Delayed strategy for renal-replacement therapy
Number of subjects: 488
Study 28173843 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of treatment (insulin pumps)
Number of subjects: 22
Study 25060056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 441
Study 25060056 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 441
Study 23939354 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face prompting of critical care physicians
Number of subjects: 296
Study 23939354 — intervention group
Group type: COMPARATOR
Intervention: Unprompted electronic checklist
Number of subjects: 296
Study 22108478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol® + ICS (100 mg daily, 50 mg in the morning and 50 mg in the evening)
Number of subjects: 76
Study 22108478 — intervention group
Group type: COMPARATOR
Intervention: ICS only
Number of subjects: 76
Study 22108478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol® + ICS
Number of subjects: 76
Study 18262445 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CE-US)
Number of subjects: 31
Study 18262445 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D time‐of‐flight magnetic resonance angiography (2D‐TOF MRA)
Number of subjects: 31
Study 18262445 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced magnetic resonance angiography (CE‐MRA)
Number of subjects: 31
Study 18262445 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 31
Study 17017821 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) 6 mg/24 hours to 12 mg/24 hours
Number of subjects: 265
Study 17017821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 12705366 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (Lucrin) 3.75 mg administered s.c. monthly
Number of subjects: 44
Study 12705366 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy age and puberty matched girls)
Number of subjects: 44
Study 10997967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 114
Study 10997967 — intervention group
Group type: COMPARATOR
Intervention: Control (no cytoreductive therapy)
Number of subjects: 114
Study 10997967 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan plus Hydroxyurea (HU)
Number of subjects: 114
Study 10997967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea only
Number of subjects: 114
Study 10997967 — intervention group
Group type: EXPERIMENTAL
Intervention: No chemotherapy
Number of subjects: 114
Study 8774038 — intervention group
Group type: EXPERIMENTAL
Intervention: Different rates of force application (ramp)
Number of subjects: 24
Study 8774038 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-mediated myometric procedure
Number of subjects: 24
Study 1594210 — intervention group
Group type: EXPERIMENTAL
Intervention: Schocket shunt
Number of subjects: 0
Study 1594210 — intervention group
Group type: COMPARATOR
Intervention: Molteno implant
Number of subjects: 0
Study 1594210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 6690877 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation laryngeal prosthesis
Number of subjects: 0
Study 6690877 — intervention group
Group type: COMPARATOR
Intervention: Currently existing laryngeal prosthesis
Number of subjects: 0
Study 31577727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS) prediction
Number of subjects: 3234
Study 31577727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for disease-specific survival (DSS) prediction
Number of subjects: 3234
Study 26314821 — intervention group
Group type: EXPERIMENTAL
Intervention: Urticaria Patient Daily Diary (UPDD)
Number of subjects: 975
Study 24279738 — intervention group
Group type: COMPARATOR
Intervention: Avocado Added (AA)
Number of subjects: 26
Study 24279738 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 26
Study 21292847 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% Calorie Restriction (CR)
Number of subjects: 0
Study 21292847 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Calorie Diet (LCD, 890 kcal/day until 15% weight loss, then weight maintenance)
Number of subjects: 0
Study 21292847 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Calorie Restriction (CR)
Number of subjects: 0
Study 21292847 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% Calorie Restriction (CR)
Number of subjects: 0
Study 21292847 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 19994680 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Fengchi (GB 20) and 'Gongxue'
Number of subjects: 60
Study 19994680 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Flunarizine hydrochlorid capsules)
Number of subjects: 60
Study 19994680 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 19994680 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 60
Study 19994680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 17341173 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation targeting the hemisphere where the stroke occurred to enhance cortical excitability.
Number of subjects: 0
Study 17341173 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation targeting the intact hemisphere to suppress cortical excitability.
Number of subjects: 0
Study 15083779 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis patients
Number of subjects: 85
Study 15083779 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI components (desquamation on upper limbs)
Number of subjects: 85
Study 15083779 — intervention group
Group type: EXPERIMENTAL
Intervention: PASI components (desquamation on scalp)
Number of subjects: 85
Study 11282668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lidocaine (1 mL of 4% lidocaine)
Number of subjects: 49
Study 11282668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 49
Study 9919184 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy and massage
Number of subjects: 0
Study 8310996 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-44 g pyruvate (n = 17)
Number of subjects: 34
Study 8310996 — intervention group
Group type: COMPARATOR
Intervention: 18-35 g polyglucose (placebo, Polycose, n = 17)
Number of subjects: 34
Study 3335988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg metoclopramide orally, 40‐45 min before procedure
Number of subjects: 18
Study 3335988 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally, 40‐45 min before procedure
Number of subjects: 18
Study 31917874 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic lancet
Number of subjects: 105
Study 31917874 — intervention group
Group type: COMPARATOR
Intervention: Needle
Number of subjects: 105
Study 31043758 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal blood pressure‐raising alleles
Number of subjects: 230069
Study 31043758 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct fetal genetic effects of maternal blood pressure‐raising alleles
Number of subjects: 230069
Study 31043758 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal birth weight‐lowering genotypes
Number of subjects: 230069
Study 27655380 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral fundoplication (TF)
Number of subjects: 63
Study 25090135 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.014‐inch superelastic nickel‐titanium (NiTi)
Number of subjects: 74
Study 25090135 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.014‐inch thermoelastic NiTi
Number of subjects: 74
Study 25090135 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.014‐inch conventional NiTi
Number of subjects: 74
Study 24330986 — intervention group
Group type: EXPERIMENTAL
Intervention: ER XIE TING GRANULES
Number of subjects: 1489
Study 24330986 — intervention group
Group type: COMPARATOR
Intervention: Smectite powder
Number of subjects: 1489
Study 21314678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 18430310 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 31
Study 18430310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16949492 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus trimetazidine (20 mg three times daily)
Number of subjects: 55
Study 16949492 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 55
Study 12882414 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock music video with suicidal content
Number of subjects: 237
Study 12882414 — intervention group
Group type: COMPARATOR
Intervention: Rock music video without suicidal content
Number of subjects: 237
Study 12882414 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock music with suicidal content
Number of subjects: 237
Study 12882414 — intervention group
Group type: COMPARATOR
Intervention: Rock music with neutral content
Number of subjects: 237
Study 10671804 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls risk factor assessment/modification and seated balance exercise training (n = 77)
Number of subjects: 133
Study 10671804 — intervention group
Group type: COMPARATOR
Intervention: Reminiscence therapy (n = 56)
Number of subjects: 133
Study 9054841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 18682
Study 9054841 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline isolated systolic hypertension
Number of subjects: 18682
Study 8472698 — intervention group
Group type: EXPERIMENTAL
Intervention: Light exercise (25W)
Number of subjects: 5
Study 8472698 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from rest to exercise
Number of subjects: 5
Study 3747800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 ppm O3
Number of subjects: 10
Study 3747800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18 ppm O3
Number of subjects: 10
Study 3747800 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.24 ppm O3
Number of subjects: 10
Study 3747800 — intervention group
Group type: COMPARATOR
Intervention: Filtered Air (FA)
Number of subjects: 10
Study 31414245 — intervention group
Group type: EXPERIMENTAL
Intervention: CaringGuidance™ plus usual care
Number of subjects: 100
Study 31414245 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 100
Study 30381128 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukodeplated RBC transfusion (Group I)
Number of subjects: 48
Study 30381128 — intervention group
Group type: COMPARATOR
Intervention: Suspended RBC transfusion (Group II)
Number of subjects: 48
Study 30381128 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 48
Study 30381128 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (Leukodeplated RBC)
Number of subjects: 48
Study 30381128 — intervention group
Group type: COMPARATOR
Intervention: Group II (Suspended RBC)
Number of subjects: 48
Study 27499378 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR levels (measured in log2 ng/mL)
Number of subjects: 1503
Study 24606877 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer questionnaire asking for multiple nominations of opinion leaders
Number of subjects: 100
Study 24606877 — intervention group
Group type: COMPARATOR
Intervention: Shorter questionnaire asking for a list of named 'champions'
Number of subjects: 100
Study 22704411 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Feitai Capsule
Number of subjects: 60
Study 22704411 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 60
Study 20182833 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmentally tailored intervention
Number of subjects: 1971
Study 20182833 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic tailored intervention
Number of subjects: 1971
Study 20182833 — intervention group
Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 1971
Study 18380954 — intervention group
Group type: EXPERIMENTAL
Intervention: Red clover isoflavones
Number of subjects: 401
Study 18380954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 15772459 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic complex remedy Euphorbium compositum nasal drops SN
Number of subjects: 0
Study 15772459 — intervention group
Group type: COMPARATOR
Intervention: Xylometazoline
Number of subjects: 0
Study 12610033 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision support tool (DMA)
Number of subjects: 598
Study 12610033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to DMA)
Number of subjects: 598
Study 10353674 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (PTFE) graft
Number of subjects: 108
Study 10353674 — intervention group
Group type: COMPARATOR
Intervention: Gelatin-sealed knitted Dacron graft
Number of subjects: 108
Study 7536999 — intervention group
Group type: EXPERIMENTAL
Intervention: iloprost intravenously for 6 hours per day (mean dose: 1.7 ng/kg/min)
Number of subjects: 30
Study 7536999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no trial therapy)
Number of subjects: 30
Study 7536999 — intervention group
Group type: EXPERIMENTAL
Intervention: iloprost treatment
Number of subjects: 30
Study 2197297 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle stretching relaxation procedures (SR)
Number of subjects: 8
Study 2197297 — intervention group
Group type: COMPARATOR
Intervention: Tense-release techniques (TR)
Number of subjects: 8
Study 2197297 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 8
Study 7003797 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clemastine
Number of subjects: 10
Study 7003797 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 10
Study 31112954 — intervention group
Group type: EXPERIMENTAL
Intervention: Desidustat 100 mg
Number of subjects: 117
Study 31112954 — intervention group
Group type: EXPERIMENTAL
Intervention: Desidustat 150 mg
Number of subjects: 117
Study 31112954 — intervention group
Group type: EXPERIMENTAL
Intervention: Desidustat 200 mg
Number of subjects: 117
Study 31112954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 28851409 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG device (Kardia Mobile) recording twice daily for 1 year
Number of subjects: 200
Study 28851409 — intervention group
Group type: COMPARATOR
Intervention: 7-day Holter monitor
Number of subjects: 200
Study 26374305 — intervention group
Group type: EXPERIMENTAL
Intervention: Reablement
Number of subjects: 750
Study 26374305 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 750
Study 23876095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy on TMJ region
Number of subjects: 85
Study 23876095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy on masseter and temporal muscles
Number of subjects: 85
Study 23876095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy on both TMJ region and muscles
Number of subjects: 85
Study 23876095 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 85
Study 21799131 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm humid air (25°C, 94% relative humidity)
Number of subjects: 21
Study 21799131 — intervention group
Group type: COMPARATOR
Intervention: Cold dry air (4°C, 37% relative humidity)
Number of subjects: 21
Study 19730208 — intervention group
Group type: EXPERIMENTAL
Intervention: L2 block
Number of subjects: 37
Study 19730208 — intervention group
Group type: COMPARATOR
Intervention: Control block
Number of subjects: 37
Study 17573961 — intervention group
Group type: EXPERIMENTAL
Intervention: PICO templates (Protocol A)
Number of subjects: 31
Study 17573961 — intervention group
Group type: EXPERIMENTAL
Intervention: PICO templates (Protocol B)
Number of subjects: 31
Study 17573961 — intervention group
Group type: COMPARATOR
Intervention: Standard PubMed Web interface (Protocol C)
Number of subjects: 31
Study 15046642 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lactobacillus powder
Number of subjects: 496
Study 15046642 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal lactobacillus pessaries
Number of subjects: 496
Study 15046642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 496
Study 15046642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaginal)
Number of subjects: 496
Study 15273192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cramp group (n = 21)
Number of subjects: 72
Study 15273192 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 72
Study 10396713 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% bupivacaine (group BIB)
Number of subjects: 42
Study 10396713 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of oxycodone in 10 ml of saline (group OIB)
Number of subjects: 42
Study 10396713 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of oxycodone intramuscularly (group OIM)
Number of subjects: 42
Study 7747715 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive chemoimmunotherapy (Adriamycin, interleukin-2, lymphokine-activated killer cells)
Number of subjects: 24
Study 7747715 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Adriamycin alone)
Number of subjects: 24
Study 7747715 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 24
Study 7747715 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive chemoimmunotherapy
Number of subjects: 24
Study 7747715 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 24
Study 2174950 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip test
Number of subjects: 117
Study 2174950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 117
Study 2174950 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stressors (arithmetic, Stroop word‐color, mirror draw)
Number of subjects: 117
Study 2174950 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stressors (isometric handgrip, cold pressor)
Number of subjects: 117
Study 2174950 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender influence
Number of subjects: 117
Study 6769256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 0